BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Curran MP, McCormack PL. Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs 2008;68:1139-56. [PMID: 18484803 DOI: 10.2165/00003495-200868080-00009] [Cited by in Crossref: 56] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Mcdonald TO, Siccardi M, Moss D, Liptrott N, Giardiello M, Rannard S, Owen A. The Application of Nanotechnology to Drug Delivery in Medicine. Nanoengineering. Elsevier; 2015. pp. 173-223. [DOI: 10.1016/b978-0-444-62747-6.00007-5] [Cited by in Crossref: 6] [Article Influence: 0.9] [Reference Citation Analysis]
2 Sultana S, Alzahrani N, Alzahrani R, Alshamrani W, Aloufi W, Ali A, Najib S, Siddiqui NA. Stability issues and approaches to stabilised nanoparticles based drug delivery system. J Drug Target 2020;28:468-86. [PMID: 31984810 DOI: 10.1080/1061186X.2020.1722137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Fishbane S, Roger SD, Martin E, Runyan G, O'Neil J, Qiu P, Locatelli F. Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa. Clin J Am Soc Nephrol 2013;8:538-45. [PMID: 23243269 DOI: 10.2215/CJN.03440412] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
4 Kuwahara M, Hasumi S, Mandai S, Tanaka T, Shikuma S, Akita W, Mori Y, Sasaki S. Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients. Clin Exp Nephrol 2014;18:755-62. [DOI: 10.1007/s10157-013-0919-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
5 Macdougall IC, Ashenden M. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv Chronic Kidney Dis 2009;16:117-30. [PMID: 19233071 DOI: 10.1053/j.ackd.2008.12.010] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 4.5] [Reference Citation Analysis]
6 Oh J, Joo KW, Chin HJ, Chae DW, Kim SG, Kim SJ, Chung W, Kim S, Huh W, Oh HY, Choi BS, Yang CW, Kim S. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis. J Korean Med Sci 2014;29:76-83. [PMID: 24431909 DOI: 10.3346/jkms.2014.29.1.76] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
7 Hirai K, Ookawara S, Miyazawa H, Ito K, Ueda Y, Kaku Y, Hoshino T, Kimura SI, Yoshida I, Kakuta S, Morishita Y, Tabei K. Successful treatment of a hemodialyzed patient with pure red cell aplasia associated with epoetin beta pegol therapy with cyclosporine. CEN Case Rep 2016;5:78-82. [PMID: 28509169 DOI: 10.1007/s13730-015-0196-8] [Reference Citation Analysis]
8 Schütz CA, Juillerat-jeanneret L, Mueller H, Lynch I, Riediker M. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine 2013;8:449-67. [DOI: 10.2217/nnm.13.8] [Cited by in Crossref: 155] [Cited by in F6Publishing: 144] [Article Influence: 17.2] [Reference Citation Analysis]
9 Chang TC, Chen BM, Lin WW, Yu PH, Chiu YW, Chen YT, Wu JY, Cheng TL, Hwang DY, Roffler AS. Both IgM and IgG Antibodies Against Polyethylene Glycol Can Alter the Biological Activity of Methoxy Polyethylene Glycol-Epoetin Beta in Mice. Pharmaceutics 2019;12:E15. [PMID: 31877813 DOI: 10.3390/pharmaceutics12010015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
10 Alsalimy N, Awaisu A. Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review. Int J Clin Pharm 2014;36:1115-25. [DOI: 10.1007/s11096-014-0023-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chen BM, Cheng TL, Roffler SR. Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies. ACS Nano 2021;15:14022-48. [PMID: 34469112 DOI: 10.1021/acsnano.1c05922] [Reference Citation Analysis]
12 Su H, Wang Y, Gu Y, Bowman L, Zhao J, Ding M. Potential applications and human biosafety of nanomaterials used in nanomedicine. J Appl Toxicol 2018;38:3-24. [PMID: 28589558 DOI: 10.1002/jat.3476] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 9.4] [Reference Citation Analysis]
13 Vandenplas Y, Simoens S, Van Wilder P, Vulto AG, Huys I. Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis. Front Pharmacol 2021;12:644187. [PMID: 33953678 DOI: 10.3389/fphar.2021.644187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Nadim AH, Abd El-Aal MA, Al-Ghobashy MA, El-Saharty YS. Facile imprinted polymer for label-free highly selective potentiometric sensing of proteins: case of recombinant human erythropoietin. Anal Bioanal Chem 2021;413:3611-23. [PMID: 33866391 DOI: 10.1007/s00216-021-03325-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Sherman MR, Williams LD, Sobczyk MA, Michaels SJ, Saifer MG. Role of the methoxy group in immune responses to mPEG-protein conjugates. Bioconjug Chem 2012;23:485-99. [PMID: 22332808 DOI: 10.1021/bc200551b] [Cited by in Crossref: 91] [Cited by in F6Publishing: 77] [Article Influence: 9.1] [Reference Citation Analysis]
16 Sharma D, Sharma N, Pathak M, Agrawala PK, Basu M, Ojha H. Nanotechnology-based drug delivery systems. Drug Targeting and Stimuli Sensitive Drug Delivery Systems. Elsevier; 2018. pp. 39-79. [DOI: 10.1016/b978-0-12-813689-8.00002-1] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
17 Goldsmith D. 2009: a requiem for rHuEPOs--but should we nail down the coffin in 2010? Clin J Am Soc Nephrol 2010;5:929-35. [PMID: 20413441 DOI: 10.2215/CJN.09131209] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
18 Hermanson T, Bennett CL, Macdougall IC. Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise. Expert Opin Drug Saf 2016;15:1421-6. [PMID: 27551882 DOI: 10.1080/14740338.2016.1218467] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
19 Ekladious I, Colson YL, Grinstaff MW. Polymer–drug conjugate therapeutics: advances, insights and prospects. Nat Rev Drug Discov 2019;18:273-94. [DOI: 10.1038/s41573-018-0005-0] [Cited by in Crossref: 242] [Cited by in F6Publishing: 213] [Article Influence: 60.5] [Reference Citation Analysis]
20 Esposito C, Abelli M, Sileno G, Migotto C, Torreggiani M, Serpieri N, Maggi N, Esposito V, Grosjean F, Scaramuzzi M, Montagna F, Canton A. Effects of Continuous Erythropoietin Receptor Activator (CERA) in Kidney Transplant Recipients. Transplantation Proceedings 2012;44:1916-7. [DOI: 10.1016/j.transproceed.2012.05.063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
21 El-Aal MAA, Al-Ghobashy MA, El-Saharty YS. Preparation and characterization of 96-well microplates coated with molecularly imprinted polymer for determination and biosimilarity assessment of recombinant human erythropoietin. J Chromatogr A 2021;1641:462012. [PMID: 33647538 DOI: 10.1016/j.chroma.2021.462012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Macdougall IC. New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis 2012;59:444-51. [PMID: 22192713 DOI: 10.1053/j.ajkd.2011.11.013] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
23 Cano F, Alarcon C, Azocar M, Lizama C, Maria Lillo A, Delucchi A, Gonzalez M, Arellano P, Delgado I, Droguett MT. Continuous EPO receptor activator therapy of anemia in children under peritoneal dialysis. Pediatr Nephrol 2011;26:1303-10. [PMID: 21416403 DOI: 10.1007/s00467-011-1846-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
24 Greish K, Mathur A, Bakhiet M, Taurin S. Nanomedicine: is it lost in translation? Ther Deliv 2018;9:269-85. [PMID: 29495928 DOI: 10.4155/tde-2017-0118] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
25 Dharmarajan TS, Widjaja D. Erythropoiesis-stimulating agents in anemia: use and misuse. J Am Med Dir Assoc 2009;10:607-16. [PMID: 19883882 DOI: 10.1016/j.jamda.2009.05.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
26 Wedekin M, Ehrich JHH, Pape L. Effective treatment of anemia in pediatric kidney transplant recipients with methoxy polyethylene glycol-epoetin beta: Effective treatment of anemia with MPG-EPO. Pediatric Transplantation 2011;15:329-33. [DOI: 10.1111/j.1399-3046.2011.01476.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
27 Bartnicki P, Rysz J, Franczyk B, Baj Z, Majewska E. Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease. Oxid Med Cell Longev 2016;2016:9879615. [PMID: 27034745 DOI: 10.1155/2016/9879615] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
28 Atkinson TS, Kahn MJ. Blood doping: Then and now. A narrative review of the history, science and efficacy of blood doping in elite sport. Blood Reviews 2020;39:100632. [DOI: 10.1016/j.blre.2019.100632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
29 Abed HS, Al-Ghobashy MA, Fathalla FA, Salem MY. Evaluation of the combined effects of pegylation and glycosylation on the stability of erythropoietin using a stability-indicating SE-HPLC. Biologicals 2017;50:129-36. [PMID: 28958787 DOI: 10.1016/j.biologicals.2017.08.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
30 Kuwahara M, Arai Y, Takehara E, Sasaki Y, Yoshimine T, Kusaka K, Shikuma S, Akita W, Uchida S. Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients. Clin Exp Nephrol 2016;20:585-94. [PMID: 26511877 DOI: 10.1007/s10157-015-1188-x] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
31 Rojo J, Sousa-herves A, Mascaraque A. Perspectives of Carbohydrates in Drug Discovery. Comprehensive Medicinal Chemistry III. Elsevier; 2017. pp. 577-610. [DOI: 10.1016/b978-0-12-409547-2.12311-x] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
32 Sinclair AM. Erythropoiesis stimulating agents: approaches to modulate activity. Biologics. 2013;7:161-174. [PMID: 23847411 DOI: 10.2147/btt.s45971] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
33 Schmid H. Cost-effectiveness of continuous erythropoietin receptor activator in anemia. Clinicoecon Outcomes Res 2014;6:319-30. [PMID: 25050070 DOI: 10.2147/CEOR.S46930] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
34 Hirai T, Nishizawa Y, Nakazono H, Asai M, Yamashita H, Sasaki A, Yamashita T, Yamashita K, Shigemoto K, Harada S, Mizuiri S. Hemoglobin maintenance and dosing strategies using intravenous continuous erythropoietin receptor activator in Japanese hemodialysis patients. Ther Apher Dial 2013;17:498-503. [PMID: 24107278 DOI: 10.1111/1744-9987.12013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
35 Hermanson T, Bennett CL, Macdougall IC. Peginesatide for the treatment of anemia due to chronic kidney disease – an unfulfilled promise. Expert Opinion on Drug Safety 2016;15:1421-6. [DOI: 10.1080/14740338.2016.1218467] [Reference Citation Analysis]
36 Hu S, Yin Y. Transglutaminase for Protein Drug Modification: Pegylation and beyond. In: Tao JA, Kazlauskas R, editors. Biocatalysis for Green Chemistry and Chemical Process Development. Hoboken: John Wiley & Sons, Inc.; 2011. pp. 151-72. [DOI: 10.1002/9781118028308.ch6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
37 Gadekar V, Borade Y, Kannaujia S, Rajpoot K, Anup N, Tambe V, Kalia K, Tekade RK. Nanomedicines accessible in the market for clinical interventions. Journal of Controlled Release 2021;330:372-97. [DOI: 10.1016/j.jconrel.2020.12.034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]